Compare Incyte Corporation (INCY) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Phillips 66 — how do they compare? Incyte Corporation trades at $112.56 (market cap $22.85B), while Phillips 66 trades at $285 (market cap $112.36B). The key difference: Phillips 66 is far larger — about 4.9× Incyte Corporation's market cap, and Phillips 66 pays a 1.8% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Phillips 66 for 62 Days on average.
| INCY | PSX | |
|---|---|---|
Market Cap | $22.85B | $112.36B |
Volume | 1,927,029 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $129.93 | $281.60 |
52-Week Low | $83.80 | $126.76 |
Typical Hold Time | 33 Days | 62 Days |
Enterprise Value | $18.35B | $128.83B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Phillips 66 (PSX) trades at $271.62, up 0.68% with a bullish technical outlook near its 52-week high. The stock shows strong profitability with 24.02% ROE and 4.66% net margin, supported by three consecutive earnings beats. Recent news highlights structural refining advantages and AI implementation for operational efficiency. Current valuation metrics include a P/E of 16.07 and P/S of 0.75, suggesting reasonable pricing relative to peers.
PSX presents a compelling investment case with analyst consensus at Buy (54% rating) and $279 price target, though revenue declines from 2022-2025 pose concerns. Key risks include diesel export policy uncertainty and refining margin volatility. The company's debt reduction progress and projected 2026 earnings recovery to $7.1B support upside potential if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
